Hollander 1999.

Methods	DESIGN Description: Randomised, flexible dose, double blind, cross‐over trial, 2 week single blind placebo run‐in BLINDING Participants: Unclear Assessors: Yes Administrators: Yes ALLOCATION CONCEALMENT Method: Unclear RANDOMISATION Method: Unclear
Participants	SAMPLE Description: 40 DSM‐III‐R patients (35 randomised); average age: 34.5 years; duration of illness: 18.1 years; 57.5% male; baseline severity on BDD‐YBOCS: SCREENING Primary diagnosis: clinical interview Comorbidity: SCID‐I
Interventions	Description:clomipramine (25 ‐250 mg/d; mean dose: 138 mg/d) versus desipramine (25 ‐250 mg/d; mean dose: 147 mg/d) x 16 weeks
Outcomes	Primary outcomes: BDD‐YBOCS (10 item), BDD‐CGI, BDD‐NIMH (mod) Secondary outcomes: YBOCS, SADS, FNES, SDP, FBQ Data estimation: OC (?)
Notes	INDUSTRY SUPPORT Industry funded: No Medication provided by industry: No Any of the authors work for industry: No ADDITIONAL INFORMATION Drop‐out rates: 1 on chlomipramine, 5 on desipramine (for 12 weeks) Quality rating score: 23
Risk of bias
Bias	Authors' judgement	Support for judgement
Allocation concealment?	Unclear risk	B ‐ Unclear